Ambrisentan Patent Expiration
Ambrisentan is used for treating pulmonary arterial hypertension (PAH) in combination with tadalafil by inhibiting endothelin receptors. It was first introduced by Gilead Sciences Inc
Ambrisentan Patents
Given below is the list of patents protecting Ambrisentan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Letairis | US9549926 | Compositions and methods of treating pulmonary hypertension | Oct 14, 2031 | Gilead |
| Letairis | US8377933 | Method for treating a pulmonary hypertension condition | Dec 11, 2027 | Gilead |
| Letairis | US9474752 | Method for treating a pulmonary hypertension condition | Dec 11, 2027 | Gilead |
| Letairis | USRE42462 | Carboxylic acid derivatives, their preparation and use |
Jul 29, 2018
(Expired) | Gilead |
| Letairis | US5840722 | Use of carboxylic acid derivatives as drugs |
Nov 24, 2015
(Expired) | Gilead |
| Letairis | US7109205 | Carboxylic acid derivatives, their preparation and use |
Oct 07, 2015
(Expired) | Gilead |
| Letairis | US7601730 | Carboxylic acid derivatives, their preparation and use |
Oct 07, 2015
(Expired) | Gilead |
| Letairis | US8349843 | Carboxylic acid derivatives, their preparation and use |
Oct 07, 2015
(Expired) | Gilead |
| Letairis | US5703017 | 3-(Het) arylcarboxylic acid derivatives, their preparation and intermediates for their preparation |
Dec 30, 2014
(Expired) | Gilead |
Ambrisentan's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List